Dr Reddys Laboratories shares experienced a decline of 1.76% to Rs 1,252.80 in Friday's session, accompanied by high trading volume. The stock is a constituent of the Nifty 50 index.
Financial Performance:
The following table summarizes the consolidated quarterly financial performance of Dr Reddys Laboratories:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 7,696.10 Crore | Rs 8,038.20 Crore | Rs 8,381.20 Crore | Rs 8,528.40 Crore | Rs 8,572.10 Crore |
| Net Profit | Rs 1,386.50 Crore | Rs 1,335.80 Crore | Rs 1,400.00 Crore | Rs 1,581.20 Crore | Rs 1,409.70 Crore |
| EPS | 83.61 | 80.45 | 16.97 | 19.12 | 17.04 |
The revenue for Dr Reddys Laboratories has shown a consistent increase over the quarters, from Rs 7,696.10 Crore in June 2024 to Rs 8,572.10 Crore in June 2025. The net profit also saw fluctuations, with a peak of Rs 1,581.20 Crore in March 2025 and a recent value of Rs 1,409.70 Crore in June 2025.
The following table summarizes the consolidated yearly financial performance:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 19,047.50 Crore | Rs 21,545.20 Crore | Rs 24,669.70 Crore | Rs 28,011.10 Crore | Rs 32,643.90 Crore |
| Net Profit | Rs 1,903.60 Crore | Rs 2,112.20 Crore | Rs 4,470.30 Crore | Rs 5,563.20 Crore | Rs 5,703.50 Crore |
| EPS | 117.67 | 131.57 | 271.47 | 335.22 | 67.89 |
| BVPS | 1,060.20 | 1,154.59 | 1,397.73 | 1,693.93 | 402.27 |
| ROE | 11.06 | 11.35 | 19.35 | 19.74 | 16.85 |
| Debt to Equity | 0.15 | 0.16 | 0.05 | 0.06 | 0.12 |
The yearly revenue has steadily increased from Rs 19,047.50 Crore in 2021 to Rs 32,643.90 Crore in 2025. Similarly, the net profit has risen from Rs 1,903.60 Crore in 2021 to Rs 5,703.50 Crore in 2025. The EPS has increased significantly from 117.67 in 2021 to 335.22 in 2024, before falling to 67.89 in 2025. The debt to equity ratio has remained relatively stable, fluctuating between 0.05 and 0.16 over the years.
Consolidated yearly income statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 32,643 | 28,011 | 24,669 | 21,545 | 19,047 |
| Other Income | 1,097 | 894 | 1,055 | 484 | 291 |
| Total Income | 33,741 | 28,905 | 25,725 | 22,029 | 19,338 |
| Total Expenditure | 25,800 | 21,548 | 19,570 | 18,942 | 16,406 |
| EBIT | 7,940 | 7,357 | 6,154 | 3,086 | 2,932 |
| Interest | 282 | 171 | 142 | 95 | 97 |
| Tax | 1,954 | 1,623 | 1,541 | 878 | 931 |
| Net Profit | 5,703 | 5,563 | 4,470 | 2,112 | 1,903 |
Consolidated quarterly income statement:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 8,572 | 8,528 | 8,381 | 8,038 | 7,696 |
| Other Income | 290 | 522 | 150 | 307 | 187 |
| Total Income | 8,862 | 9,050 | 8,531 | 8,345 | 7,883 |
| Total Expenditure | 6,874 | 6,985 | 6,579 | 6,358 | 5,946 |
| EBIT | 1,987 | 2,065 | 1,951 | 1,987 | 1,936 |
| Interest | 83 | 65 | 81 | 75 | 59 |
| Tax | 495 | 418 | 470 | 575 | 490 |
| Net Profit | 1,409 | 1,581 | 1,400 | 1,335 | 1,386 |
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 4,642 | 4,543 | 5,887 | 2,810 | 3,570 |
| Investing Activities | -5,807 | -4,028 | -4,137 | -2,638 | -2,266 |
| Financing Activities | 1,891 | -376 | -2,686 | -242 | -29 |
| Others | 22 | -5 | 28 | 73 | 11 |
| Net Cash Flow | 748 | 132 | -907 | 3 | 1,285 |
Balance Sheet:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 83 | 83 | 83 | 83 | 83 |
| Reserves & Surplus | 33,466 | 28,171 | 23,202 | 19,129 | 17,558 |
| Current Liabilities | 13,033 | 9,588 | 8,572 | 9,765 | 8,103 |
| Other Liabilities | 2,843 | 1,021 | 426 | 768 | 871 |
| Total Liabilities | 49,426 | 38,863 | 32,285 | 29,746 | 26,616 |
| Fixed Assets | 19,378 | 11,294 | 9,701 | 8,867 | 9,210 |
| Current Assets | 25,018 | 24,805 | 20,425 | 17,782 | 14,550 |
| Other Assets | 5,030 | 2,763 | 2,157 | 3,097 | 2,855 |
| Total Assets | 49,426 | 38,863 | 32,285 | 29,746 | 26,616 |
| Contingent Liabilities | 1,738 | 2,091 | 997 | 936 | 1,077 |
Ratios:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 67.89 | 335.22 | 271.47 | 131.57 | 117.67 |
| Diluted Eps (Rs.) | 67.79 | 334.59 | 270.90 | 131.21 | 117.34 |
| Book Value /Share (Rs.) | 402.27 | 1,693.93 | 1,397.73 | 1,154.59 | 1,060.20 |
| Dividend/Share (Rs.) | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 |
| Face Value | 1 | 5 | 5 | 5 | 5 |
| Gross Profit Margin (%) | 29.54 | 31.51 | 30.01 | 19.73 | 21.84 |
| Operating Margin (%) | 24.32 | 26.26 | 24.94 | 14.32 | 15.39 |
| Net Profit Margin (%) | 17.47 | 19.86 | 18.12 | 9.80 | 9.99 |
| Return on Equity (%) | 16.85 | 19.74 | 19.35 | 11.35 | 11.06 |
| ROCE (%) | 21.81 | 25.13 | 25.95 | 15.44 | 15.84 |
| Return On Assets (%) | 11.44 | 14.35 | 13.96 | 7.33 | 7.33 |
| Current Ratio (X) | 1.92 | 2.59 | 2.38 | 1.82 | 1.80 |
| Quick Ratio (X) | 1.37 | 1.92 | 1.82 | 1.30 | 1.24 |
| Debt to Equity (x) | 0.12 | 0.06 | 0.05 | 0.16 | 0.15 |
| Interest Coverage Ratios (X) | 34.09 | 51.59 | 51.85 | 44.39 | 42.90 |
| Asset Turnover Ratio (%) | 0.74 | 0.79 | 0.80 | 0.56 | 0.60 |
| Inventory Turnover Ratio (X) | 0.84 | 0.80 | 0.85 | 0.86 | 1.03 |
| 3 Yr CAGR Sales (%) | 23.09 | 21.27 | 18.67 | 18.10 | 15.49 |
| 3 Yr CAGR Net Profit (%) | 64.32 | 70.95 | 50.64 | 5.26 | 44.44 |
| P/E (x) | 16.85 | 3.67 | 3.41 | 6.53 | 7.68 |
| P/B (x) | 2.84 | 3.63 | 3.31 | 3.73 | 4.26 |
| EV/EBITDA (x) | 10.11 | 11.62 | 10.32 | 17.01 | 18.20 |
| P/S (x) | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 |
Corporate Actions:
Dr Reddys Laboratories announced a final dividend of Rs 8.00 per share (800%) on May 9, 2025, with an effective date of July 10, 2025. Earlier dividends include Rs 40.00 per share (800%) on May 7, 2024, effective July 16, 2024, and Rs 40.00 per share (800%) on May 10, 2023, effective July 11, 2023.
The company has a history of bonus issues, including a 1:1 bonus on May 31, 2006 (ex-date August 28, 2006), and a 2:1 bonus on March 24, 1994 (ex-date April 8, 1994).
Dr Reddys Laboratories had a stock split on July 27, 2024, with the face value changing from Rs 5 to Rs 1 (ex-date October 28, 2024).
Moneycontrol analysis on September 25, 2025, indicated a neutral sentiment on the stock.
Dr Reddys Laboratories shares experienced a decline of 1.76% to Rs 1,252.80 in Friday's session amid high volume.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
